# Dalpiciclib Plus Letrozole and Capecitabine

> **NCT05469750** · PHASE2 · UNKNOWN · sponsor: **Fujian Medical University Union Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib+ letrozole +capecitabine

## Key facts

- **NCT ID:** NCT05469750
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-10
- **Primary completion:** 2023-08
- **Final completion:** 2024-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469750, "Dalpiciclib Plus Letrozole and Capecitabine". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05469750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*